[O18] Oral Session 18　消化器3（下部消化管-大腸癌2）
【E】

[O18-3] Impact of plasma VEGF-A, VEGF-D and PlGF on the efficacy of 2nd-line chemotherapy combined with biologics in mCRC

^○Kentaro Yamazaki¹, Satoshi Yuki², Hiroya Taniguchi³, Hideaki Bando⁴, Yu Sunakawa⁵, Manabu Shiozawa⁶, Hisateru Yasui⁷, Naoki Takahashi⁹, Hironaga Satake⁹, Nobuhisa Matsuhashi¹⁰, Akiyoshi Kanazawa¹¹, Yosuke Horita¹², Masahiro Goto¹³, Naohiro Okano¹⁴, Kaname Yamashita¹⁵, Akihito Tsuji¹⁶, Hiromichi Ebi¹⁷, Yukiko Abe¹⁸, Shogo Nomura¹⁹, Takayuki Yoshino⁴ (1.Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 2.Department of Gastroenterology and Hepatology, Hokkaido University Hospital, 3.Department of Clinical Oncology, Aichi Cancer Center Hospital, 4.Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 5.Department of Clinical Oncology, St. Marianna University School of Medicine, 6.Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 7.Department of Medical Oncology, Kobe City Medical Center General Hospital, 8.Department of Gastroenterology, Saitama Cancer Center, 9.Cancer Treatment Center, Kansai Medical University Hospital, 10.Department of Gastroenterological Surgery, Gifu University Hospital, 11.Department of Surgery, Shimane Prefectural Central Hospital, 12.Department of Gastroenterological Oncology, Saitama Medical University International Medical Center, 13.Cancer Chemotherapy Center, Osaka Medical College Hospital, 14.Department of Medical Oncology, Kyorin University Faculty of Medicine, 15.Division of Medical Oncology Cancer Research Institute, Kanazawa University, 16.Department of Clinical Oncology, Faculty of Medicine, Kagawa University, 17.Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, 18.Board member, G&G Science Co., Ltd., 19.Clinical Research Support Office, National Cancer Center Hospital East)